Huasen Pharmaceutical (stock code: 002907) is a national key high-tech enterprise integrating scientific research, production and sales, and a large comprehensive modern pharmaceutical enterprise in China. It has established a post-Bo Scientific Research Workstation and Chongqing City Haizhi workstation. Huasen Pharmaceuticals is owned by Beijing Huasen Inno Biotechnology Co., Ltd., Beijing Bosen Biotechnology Co., Ltd., Pharscin US Inc. (Huasen Pharmaceutical (US) Co., Ltd.), Chongqing Huasen Biotechnology Co., Ltd., Chongqing Huasen Pharmaceutical Co., Ltd., Chongqing Huasen Pharmacy Retail Chain Co., Ltd.

Huasen Pharmaceuticals is based on the concept of "technology-led, innovation-driven, inheriting the essence, adhering to the truth and innovation", and creating high-quality products that are "specialized, refined, special and new". Currently, the company has 77 drug approval documents, including Chinese patent medicines, chemical raw materials and preparations, and has 1 US ANDA equity product, including 56 drugs in the national "medical insurance" catalog, 49 national drug standards, and 72 patents. It undertakes 120 scientific and technological research and development projects in various national, provincial and municipal ministries and commissions.

In terms of innovative drug research and development, Watson Pharmaceuticals (Wassen Inno) has promoted a differentiated R&D pipeline and is committed to building an innovative drug research and development team with an international perspective, focusing on small-molecular drugs in the fields of tumors, tumor immunity and self-invigorating diseases. Development has already had 4 independently developed innovative drugs in tumor category 1.1, and its potential indications cover tumor immunity and lung cancer, breast cancer, colorectal cancer, pancreatic cancer and other solid tumors; it has been built to develop multiple innovative drugs. platform.

In terms of external cooperation in innovative drugs, we cooperated with the scientific research achievement conversion platform of the scientist team of the National Key Laboratory of Biotherapy of Sichuan University to invest in the establishment of Chengdu Aoru Pharmaceutical Co., Ltd., a technology platform based on artificial intelligence drug discovery dedicated to small molecule targeting New drug research and development company for innovative drugs; cooperate with Zhongke Computing Technology Western Research Institute and Beijing Zheyuan Technology Co., Ltd. to screen new tumor drug targets, drug candidate development, translational medicine research, preclinical and clinical development, registration and application, market approval and other work to create a new height for biomedical innovation.

In terms of generic drugs, Chinese patent medicines and special medical food research and development, the company has implemented the R&D strategy of "excellent production costs, fast R&D speed, and high technical barriers", and has laid out the digestive system, mental nervous system, respiratory system, tumor, and postoperative reduction. In the fields of heavy and heavy industry, through the continuous accumulation of project experience, eight national R&D technologies have been established, including “Raw Materials Engineering Transformation Research Platform, Industrial Pharmaceutical Prescription Design and Process Amplification Research Platform, CMC (Chemical and Quality Control) and Impurity Quantitative Analysis Research Platform”. The company has established a testing center in the construction of common R&D platforms, which has passed the CNAS certification.

Huasen Pharmaceutical takes "developing good medicines, healthy human beings, and achieving employees" as its corporate mission, upholds the values ​​of "integrity, diligence, gratitude, learning, teamwork, innovation", and uses solid steps to "make good Chinese medicine and go to the world" The Huasen Dream has been striving forever, contributing to the construction of the Chengdu-Chongqing Twin Cities Economic Circle and contributing to the realization of the Chinese dream of the great rejuvenation of the Chinese nation.